at-100
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Apr 30, 2021 (NCT04662151)
Timeline
Indications
Mechanism of action
- Heat shock protein HSP 60Supplementation
HSPD1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650375 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06897839 | Phase 2/Phase 3 (Phase 3) | Feb 3, 2025 | Airway Therapeutics, Inc. |
| NCT04659122 | Phase 1 | Aug 17, 2021 | Airway Therapeutics, Inc. |
| NCT04662151 | Phase 1 | Apr 30, 2021 | Airway Therapeutics, Inc., Emory University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Airway Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2021 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1